JP2016212116A5 - - Google Patents

Download PDF

Info

Publication number
JP2016212116A5
JP2016212116A5 JP2016153332A JP2016153332A JP2016212116A5 JP 2016212116 A5 JP2016212116 A5 JP 2016212116A5 JP 2016153332 A JP2016153332 A JP 2016153332A JP 2016153332 A JP2016153332 A JP 2016153332A JP 2016212116 A5 JP2016212116 A5 JP 2016212116A5
Authority
JP
Japan
Prior art keywords
prognosis
survival
diagnosis
subject
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016153332A
Other languages
English (en)
Other versions
JP2016212116A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016212116A publication Critical patent/JP2016212116A/ja
Publication of JP2016212116A5 publication Critical patent/JP2016212116A5/ja
Pending legal-status Critical Current

Links

Claims (11)

  1. 卵巣癌を有するかまたは有する疑いのある対象の予後を判定する方法であって、バイオマーカー、トランスフェリンおよびβ-2ミクログロビンまたはApoA1およびCA125のレベルを比較する段階を含み、該バイオマーカーのレベルが参照基準に比して高いことによって予後不良が指し示される、前記方法。
  2. CA125、Apo-A1、トランスチレチン、トランスフェリン、ヘプシジン、CTAP3、およびβ-2ミクログロビンからなる群より選択される1つまたは複数の追加的なバイオマーカーのレベルを比較する段階をさらに含む、請求項1記載の方法。
  3. 対象試料におけるCA125のレベルを参照基準に存在するレベルと比較する段階をさらに含む、請求項1記載の方法。
  4. 初回手術の根治性、診断時の年齢、および治療のうち1つまたは複数を考慮する段階をさらに含む、請求項1記載の方法。
  5. FIGO病期、腫瘍の組織型、およびCA125のうち1つまたは複数を考慮する段階をさらに含む、請求項1記載の方法。
  6. 予後が全生存期間または無増悪生存期間の予測である、請求項1記載の方法。
  7. 1つまたは複数の前記バイオマーカーにおけるレベルの増大を検出できないことによって、良好な予後が指し示される、請求項1記載の方法。
  8. 対象の予後を治療レジメンの選択に用いる、請求項1記載の方法。
  9. 不良な予後は対象が積極的な治療レジメンを必要とすることを指し示し、かつ良好な予後は対象がより積極的でない治療レジメンを必要とすることを指し示す、請求項8記載の方法。
  10. 積極的な治療レジメンがネオアジュバント化学療法を含む、請求項9記載の方法。
  11. 全生存期間または無増悪生存期間が、診断後1〜2年間の生存;診断後2〜5年間の生存;および診断後5年超の生存からなる群より選択される、請求項6記載の方法。
JP2016153332A 2010-10-22 2016-08-04 卵巣癌の患者における予後予測バイオマーカー Pending JP2016212116A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40604410P 2010-10-22 2010-10-22
US61/406,044 2010-10-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013535113A Division JP2013541716A (ja) 2010-10-22 2011-10-21 卵巣癌の患者における予後予測バイオマーカー

Publications (2)

Publication Number Publication Date
JP2016212116A JP2016212116A (ja) 2016-12-15
JP2016212116A5 true JP2016212116A5 (ja) 2017-01-26

Family

ID=45975910

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013535113A Pending JP2013541716A (ja) 2010-10-22 2011-10-21 卵巣癌の患者における予後予測バイオマーカー
JP2016153332A Pending JP2016212116A (ja) 2010-10-22 2016-08-04 卵巣癌の患者における予後予測バイオマーカー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013535113A Pending JP2013541716A (ja) 2010-10-22 2011-10-21 卵巣癌の患者における予後予測バイオマーカー

Country Status (5)

Country Link
EP (1) EP2630498A4 (ja)
JP (2) JP2013541716A (ja)
AU (1) AU2011316844A1 (ja)
CA (1) CA2818593A1 (ja)
WO (1) WO2012054824A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014182896A1 (en) * 2013-05-10 2014-11-13 Johns Hopkins University Compositions for ovarian cancer assessment having improved specificity
US10324084B2 (en) 2014-04-23 2019-06-18 Nichirei Biosciences Inc. Combination product for detecting target marker
EP3435379A1 (en) * 2017-07-27 2019-01-30 Roche Diagnostics GmbH Augmenting measurement values of biological samples
WO2019088709A2 (ko) * 2017-10-31 2019-05-09 국립암센터 Nc886 유전자를 이용한 난소암 예후 예측을 위한 정보제공방법
JP7272627B2 (ja) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 卵巣腫瘍の評価用バイオマーカー

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107765B1 (ko) * 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
DE602005023629D1 (de) * 2004-07-14 2010-10-28 Univ California Biomarker für den frühzeitigen nachweis von ovarialkarzinom
AU2006223374B2 (en) * 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
EP2993474B1 (en) * 2005-06-24 2019-06-12 Vermillion, Inc. Biomarkers for ovarian cancer: beta-2 microglobulin
WO2008060376A2 (en) * 2006-10-04 2008-05-22 The Johns Hopkins University Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
WO2008048508A2 (en) * 2006-10-13 2008-04-24 Vermillion, Inc. Prognostic biomarkers in patients with ovarian cancer
CA2691980C (en) * 2007-06-29 2022-05-10 Correlogic Systems, Inc. Predictive markers for ovarian cancer
JP5391400B2 (ja) * 2007-10-01 2014-01-15 公益財団法人ヒューマンサイエンス振興財団 α−アクチニン−4遺伝子のコピー数または発現レベルを指標とした膵癌の検出を補助する方法および診断のためのキット
EP2220506B1 (en) * 2007-10-29 2013-10-02 Vermillion, Inc. Biomarkers for the detection of early stage ovarian cancer
WO2010091763A1 (en) * 2009-02-16 2010-08-19 Atlas Antibodies Ab Rbm3 as a marker for malignant melanoma prognosis

Similar Documents

Publication Publication Date Title
JP2016212116A5 (ja)
Feng et al. Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus
Iseki et al. Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer
Hu et al. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer
Shomali et al. Can procalcitonin distinguish infectious fever from tumor‐related fever in non‐neutropenic cancer patients?
Gertler et al. Prevalence and topography of lymph node metastases in early esophageal and gastric cancer
Vashist et al. Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer
Okabe et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer
Liu et al. Superior mesenteric artery margin of posttherapy pancreaticoduodenectomy and prognosis in patients with pancreatic ductal adenocarcinoma
Varadhachary et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset
Wang et al. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma
Ghanim et al. Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis
Liu et al. The RML of lymph node metastasis was superior to the LODDS for evaluating the prognosis of gastric cancer
Ku et al. Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma
Cashin et al. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study
Zhang et al. Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer
Chen et al. A nomogram to predict prognostic value of red cell distribution width in patients with esophageal cancer
Akagi et al. Lymph node evaluation and survival in colorectal cancer: review of population-based, prospective studies
Zhang et al. The prognostic value of preoperative inflammation-based prognostic scores and nutritional status for overall survival in resected patients with nonmetastatic Siewert type II/III adenocarcinoma of esophagogastric junction
Chu et al. Impact on survival of the number of lymph nodes resected in patients with lymph node-negative gastric cancer
Mafolasire et al. Racial disparities in renal cell carcinoma: a single‐payer healthcare experience
Riveiro‐Falkenbach et al. DEK oncogene is overexpressed during melanoma progression
Sejima et al. Prognostic impact of preoperative hematological disorders and a risk stratification model in bladder cancer patients treated with radical cystectomy
Lee et al. Different lymph node staging systems in patients with gastric cancer from Korean: What is the best prognostic assessment tool?
Vessies et al. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients